Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. (August 2018)

• Record Type: Journal Article
• Authors: Sami, Musa Basseer; Bhattacharyya, Sagnik
• Is Part Of: Journal of psychopharmacology. Volume 32:Number 8(2018)
• Page Start: 825
• Page End: 849
• Publication Date: 2018-08
• Subjects: Cannabis -- psychosis -- schizophrenia -- MRI -- endocannabinoid; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881118760662
• Languages: English
• ISSNs: 0269-8811

Abstract

A substantial body of credible evidence has accumulated that suggest that cannabis use is an important potentially preventable risk factor for the development of psychotic illness and its worse prognosis following the onset of psychosis. Here we summarize the relevant evidence to argue that the time has come to investigate the neurobiological effects of cannabis in patients with psychotic disorders. In the first section we summarize evidence from longitudinal studies that controlled for a range of potential confounders of the association of cannabis use with increased risk of developing psychotic disorders, increased risk of hospitalization, frequent and longer hospital stays, and failure of treatment with medications for psychosis in those with established illness. Although some evidence has emerged that cannabis-using and non-using patients with psychotic disorders may have distinct patterns of neurocognitive and neurodevelopmental impairments, the biological underpinnings of the effects of cannabis remain to be fully elucidated. In the second and third sections we undertake a systematic review of 70 studies, including over 3000 patients with psychotic disorders or at increased risk of psychotic disorder, in order to delineate potential neurobiological and neurochemical mechanisms that may underlie the effects of cannabis in psychotic disorders and suggest avenues for future research.